Author: Steen V.D.

Source: American Journal of Clinical Dermatology, Volume 2, Number 5, 1 May 2001 , pp. 315-325(11)

Publisher: Adis International

Abstract:

Systemic sclerosis is an extremely variable disease in its manifestations and consequently, treatment needs to be individualized depending on the specific problems that each patient has. Limited scleroderma patients have a prolonged duration of Raynauds phenomenon and puffy fingers before they develop any skin thickening, digital ulcers or gastrointestinal symptoms. They are likely to present with all the classic manifestations of scleroderma. Diffuse scleroderma patients have a much more acute systemic onset with marked whole hand swelling and may initially have only subtle skin thickening. A good understanding of the differences between the natural history of limited and diffuse scleroderma will enable the physician to treat present problems and anticipate future ones more effectively. One should determine which major subset and organ systems are involved before deciding on the appropriate therapy. Advances in organ-specific therapy, particularly calcium channel antagonists in Raynauds phenomenon, proton pump inhibitors in esophageal reflux, intravenous iloprost and endothelin receptor antagonists in pulmonary hypertension, and ACE inhibitors in renal crisis, have decreased morbidity and mortality in patients with scleroderma. Studies of aggressive therapies to prevent or improve pulmonary fibrosis are in progress. Further clinical experience in wound healing, gastrointestinal malabsorption and physical therapy for loss of motion has helped patients to have a more comfortable life. In recent years, a significant number of controlled clinical trials have been performed and there has been improved understanding of the best way to perform studies and of which patients are most likely to respond to therapy. Penicillamine, methotrexate, photopheresis, relaxin, interferons, and cyclosporine have all been studied in controlled trials with variable outcomes. Although an overall remittive therapy has not yet been determined, new, potentially useful agents are being investigated.

Keywords: Cyclosporin, therapeutic use; Immunomodulators, therapeutic use; Interferons, therapeutic use; Methotrexate, therapeutic use; Penicillamine, therapeutic use; Phototherapy; Plasmapheresis; Psoralens, therapeutic use; Relaxin, therapeutic use; Research and development; Sclerosis, treatment; Systemic scleroderma, treatment; Tacrolimus, therapeutic use

Document Type: Review article

Affiliations: 1: Department of Medicine, Georgetown University, Washington, DC, USA

Publication date: 2001-05-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Dermatology
• By this author: Steen V.D.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers